Literature DB >> 21381049

Drugs that target dynamic microtubules: a new molecular perspective.

Richard A Stanton1, Kim M Gernert, James H Nettles, Ritu Aneja.   

Abstract

Microtubules have long been considered an ideal target for anticancer drugs because of the essential role they play in mitosis, forming the dynamic spindle apparatus. As such, there is a wide variety of compounds currently in clinical use and in development that act as antimitotic agents by altering microtubule dynamics. Although these diverse molecules are known to affect microtubule dynamics upon binding to one of the three established drug domains (taxane, vinca alkaloid, or colchicine site), the exact mechanism by which each drug works is still an area of intense speculation and research. In this study, we review the effects of microtubule-binding chemotherapeutic agents from a new perspective, considering how their mode of binding induces conformational changes and alters biological function relative to the molecular vectors of microtubule assembly or disassembly. These "biological vectors" can thus be used as a spatiotemporal context to describe molecular mechanisms by which microtubule-targeting drugs work.
© 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21381049      PMCID: PMC3155728          DOI: 10.1002/med.20242

Source DB:  PubMed          Journal:  Med Res Rev        ISSN: 0198-6325            Impact factor:   12.944


  222 in total

Review 1.  Microtubule-based transport systems in neurons: the roles of kinesins and dyneins.

Authors:  L S Goldstein; Z Yang
Journal:  Annu Rev Neurosci       Date:  2000       Impact factor: 12.449

Review 2.  Structural insight into microtubule function.

Authors:  E Nogales
Journal:  Annu Rev Biophys Biomol Struct       Date:  2001

3.  Microtubule structure at 8 A resolution.

Authors:  Huilin Li; David J DeRosier; William V Nicholson; Eva Nogales; Kenneth H Downing
Journal:  Structure       Date:  2002-10       Impact factor: 5.006

Review 4.  Antimicrotubular drugs binding to vinca domain of tubulin.

Authors:  Suvroma Gupta; Bhabatarak Bhattacharyya
Journal:  Mol Cell Biochem       Date:  2003-11       Impact factor: 3.396

5.  Suppression of microtubule dynamics by LY290181. A potential mechanism for its antiproliferative action.

Authors:  D Panda; J P Singh; L Wilson
Journal:  J Biol Chem       Date:  1997-03-21       Impact factor: 5.157

6.  Role of B-ring of colchicine in its binding to tubulin.

Authors:  K Ray; B Bhattacharyya; B B Biswas
Journal:  J Biol Chem       Date:  1981-06-25       Impact factor: 5.157

7.  Antiproliferative mechanism of action of cryptophycin-52: kinetic stabilization of microtubule dynamics by high-affinity binding to microtubule ends.

Authors:  D Panda; K DeLuca; D Williams; M A Jordan; L Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-04       Impact factor: 11.205

8.  MCAK, a Kin I kinesin, increases the catastrophe frequency of steady-state HeLa cell microtubules in an ATP-dependent manner in vitro.

Authors:  Cori N Newton; Michael Wagenbach; Yulia Ovechkina; Linda Wordeman; Leslie Wilson
Journal:  FEBS Lett       Date:  2004-08-13       Impact factor: 4.124

9.  Pharmacokinetic properties of noscapine.

Authors:  B Dahlström; T Mellstrand; C G Löfdahl; M Johansson
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

Review 10.  Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle.

Authors:  A Jordan; J A Hadfield; N J Lawrence; A T McGown
Journal:  Med Res Rev       Date:  1998-07       Impact factor: 12.944

View more
  119 in total

1.  TubStain: a universal peptide-tool to label microtubules.

Authors:  Carsten Theiss; Alexander Neuhaus; Wolfgang Schliebs; Ralf Erdmann
Journal:  Histochem Cell Biol       Date:  2012-07-06       Impact factor: 4.304

2.  Pyrrole-Based Antitubulin Agents: Two Distinct Binding Modalities are Predicted for C-2 Analogs in the Colchicine Site.

Authors:  Chenxiao Da; Nakul Telang; Peter Barelli; Xin Jia; John T Gupton; Susan L Mooberry; Glen E Kellogg
Journal:  ACS Med Chem Lett       Date:  2011-11-01       Impact factor: 4.345

3.  BubR1 is frequently repressed in acute myeloid leukemia and its re-expression sensitizes cells to antimitotic therapy.

Authors:  Dominik Schnerch; Andrea Schmidts; Marie Follo; Josefina Udi; Julia Felthaus; Dietmar Pfeifer; Monika Engelhardt; Ralph Wäsch
Journal:  Haematologica       Date:  2013-06-28       Impact factor: 9.941

4.  Heterocyclic-Fused Pyrimidines as Novel Tubulin Polymerization Inhibitors Targeting the Colchicine Binding Site: Structural Basis and Antitumor Efficacy.

Authors:  Souvik Banerjee; Kinsie E Arnst; Yuxi Wang; Gyanendra Kumar; Shanshan Deng; Lei Yang; Guo-Bo Li; Jinliang Yang; Stephen W White; Wei Li; Duane D Miller
Journal:  J Med Chem       Date:  2018-02-12       Impact factor: 7.446

5.  Radiosynthesis of microtubule-targeted theranostic methyl N-[5-(3'-radiohalobenzoyl)-1H-benzimidazol-2-yl]carbamates.

Authors:  Zbigniew P Kortylewicz; Janina Baranowska-Kortylewicz
Journal:  J Labelled Comp Radiopharm       Date:  2018-04-29       Impact factor: 1.921

Review 6.  Current advances of tubulin inhibitors as dual acting small molecules for cancer therapy.

Authors:  Kinsie E Arnst; Souvik Banerjee; Hao Chen; Shanshan Deng; Dong-Jin Hwang; Wei Li; Duane D Miller
Journal:  Med Res Rev       Date:  2019-02-11       Impact factor: 12.944

7.  Phase II study of the antibody-drug conjugate TAK-264 (MLN0264) in patients with metastatic or recurrent adenocarcinoma of the stomach or gastroesophageal junction expressing guanylyl cyclase C.

Authors:  Khaldoun Almhanna; Maria Luisa Limon Miron; David Wright; Antonio Cubillo Gracian; Richard A Hubner; Jean-Luc Van Laethem; Carolina Muriel López; Maria Alsina; Frederico Longo Muñoz; Johanna Bendell; Irfan Firdaus; Wells Messersmith; Zhan Ye; Adedigbo A Fasanmade; Hadi Danaee; Thea Kalebic
Journal:  Invest New Drugs       Date:  2017-02-11       Impact factor: 3.850

8.  Tubulin colchicine site binding agent LL01 displays potent antitumor efficiency both in vitro and in vivo with suitable drug-like properties.

Authors:  Jing-De Wu; Ying-Jie Cui; Yi-Gang Zhou; Long-Qian Tang; Cheng-Mei Zhang; Zhao-Peng Liu
Journal:  Invest New Drugs       Date:  2019-03-18       Impact factor: 3.850

9.  Glioma cells escaped from cytotoxicity of temozolomide and vincristine by communicating with human astrocytes.

Authors:  Weiliang Chen; Donghai Wang; Xinwen Du; Ying He; Songyu Chen; Qianqian Shao; Chao Ma; Bin Huang; Anjing Chen; Peng Zhao; Xun Qu; Xingang Li
Journal:  Med Oncol       Date:  2015-01-29       Impact factor: 3.064

10.  Developing novel C-4 analogues of pyrrole-based antitubulin agents: weak but critical hydrogen bonding in the colchicine site.

Authors:  Chenxiao Da; Nakul Telang; Kayleigh Hall; Emily Kluball; Peter Barelli; Kara Finzel; Xin Jia; John T Gupton; Susan L Mooberry; Glen E Kellogg
Journal:  Medchemcomm       Date:  2013       Impact factor: 3.597

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.